Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-01

Study Completion Date

2026-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigator's purpose is to study the population pharmacokinetics of commonly used antimicrobial agents in children of bacterial meningitis with augmented renal clearance and assess dosage individualization feasibility.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application

NCT06729619

Intracranial Infection Central Infection

ACTIVE_NOT_RECRUITING

PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection

NCT04961580

Sepsis Antibiotic Reaction

RECRUITING

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

NCT04785924

Carbapenem-Resistant Enterobacteriaceae Infection KPC Gram-Negative Bacterial Infections +1 more

WITHDRAWN PHASE4

Pharmacological Study of High Doses of Ceftriaxone in Meningitidis

NCT01745679

Meningitis Neurological Infections

COMPLETED PHASE4

A Study the Population Pharmacokinetics of Children of Infectious Disease in Central Nervous System

NCT03960905

Central Nervous System Infection

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigator's purpose is to study the population pharmacokinetics of meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid in children of bacterial meningitis with augmented renal clearance and assess dosage individualization feasibility. In this study, the investigator will detect drug concentration in both plasma and cerebrospinal fluid to construct population pharmacokinetics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacterial Meningitis Augmented Renal Clearance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)

The use of antimicrobial agents depends on the clinical practice.

meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid

Intervention Type DRUG

The use of antimicrobial agents depends on the clinical practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid

The use of antimicrobial agents depends on the clinical practice

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children have been diagnosed with bacterial meningitis with augmented renal clearance (eGFR ≥ 160 mL/(min\*1.73m2));
* Age: 2 months-18 years;
* Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and/ or linezolid used as part of regular treatment;
* Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid was administered intravenously.

Exclusion Criteria

* Patients who die within the treatment cycle;
* Severe congenital malformation;
* Receive other systemic experimental drug therapy;
* Other factors that the researchers consider unsuitable for inclusion.

Minimum Eligible Age

2 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No